financetom
Business
financetom
/
Business
/
Tesla Robotaxi Trial Reportedly Draws NHTSA Scrutiny
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Tesla Robotaxi Trial Reportedly Draws NHTSA Scrutiny
Jun 24, 2025 3:34 AM

06:14 AM EDT, 06/24/2025 (MT Newswires) -- The US National Highway Traffic Safety Administration (NHTSA) is reviewing incidents involving Tesla's (TSLA) autonomous robotaxis that appeared to violate traffic laws during the company's first day of paid operations in Austin, multiple media outlets reported late Monday.

The safety regulator is gathering information from Tesla after videos posted online showed robotaxis making illegal lane changes, crossing double-yellow lines, and exceeding posted speed limits, Bloomberg reported.

Tesla and the NHTSA did not immediately respond to MT Newswires request for comment.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Barclays re-enters talks with Brookfield about deal for UK payments business, Sky News reports
Barclays re-enters talks with Brookfield about deal for UK payments business, Sky News reports
Oct 22, 2024
Oct 22 (Reuters) - Barclays ( JJCTF ) has re-entered negotiations with Brookfield Asset Management ( BAM ) about a deal to sell a stake in its British merchant payments business to the Canadian asset manager, Sky News reported on Tuesday. A deal would make Brookfield a majority stakeholder in Barclays' ( JJCTF ) merchant payments business, while providing the...
Alvotech, Teva's Stelara Biosimilar Gets FDA Approval for New IV Presentation
Alvotech, Teva's Stelara Biosimilar Gets FDA Approval for New IV Presentation
Oct 22, 2024
07:53 AM EDT, 10/22/2024 (MT Newswires) -- Alvotech ( ALVO ) and Teva Pharmaceuticals (TEVA) said Tuesday the US Food and Drug Administration has approved a new intravenous formulation of Selarsdi, a biosimilar to Stelara, in a 130 mg/26 ml single-dose vial. Approval of Selarsdi in new presentation expands the label to cover the treatment of adults with Crohn's disease...
Moody's Q3 Adjusted Earnings, Revenue Increase; Raises 2024 Adjusted Earnings Guidance
Moody's Q3 Adjusted Earnings, Revenue Increase; Raises 2024 Adjusted Earnings Guidance
Oct 22, 2024
07:30 AM EDT, 10/22/2024 (MT Newswires) -- Moody's (MCO) reported Q3 adjusted earnings Tuesday of $3.21 per diluted share, up from $2.43 a year earlier. Analysts polled by Capital IQ expected $2.87. Revenue for the quarter ended Sept. 30 was $1.81 billion, up from $1.47 billion a year earlier. Analysts surveyed by Capital IQ expected $1.71 billion. The company said...
Lockheed Martin lifts profit, sales forecasts on strong demand for weapons
Lockheed Martin lifts profit, sales forecasts on strong demand for weapons
Oct 22, 2024
Oct 22 (Reuters) - Defense contractor Lockheed Martin ( LMT ) on Tuesday joined rival RTX in lifting annual profit and sales forecasts, driven by robust demand for military equipment amid escalating global tensions. The Bethesda, Maryland-based company now expects 2024 profit per share of $26.65, above its earlier forecast of $26.10 to $26.60. It also sees full-year sales of...
Copyright 2023-2026 - www.financetom.com All Rights Reserved